aTyr Pharma, Inc. (NASDAQ:ATYR) Given Consensus Recommendation of “Hold” by Brokerages

Shares of aTyr Pharma, Inc. (NASDAQ:ATYR) have been assigned an average recommendation of “Hold” from the seven ratings firms that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, five have given a hold rating and one has assigned a buy rating to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $23.25.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of aTyr Pharma in a report on Monday, December 29th.

aTyr Pharma Stock Performance

Shares of ATYR stock opened at $0.97 on Tuesday. aTyr Pharma has a fifty-two week low of $0.64 and a fifty-two week high of $7.29. The stock has a 50 day simple moving average of $0.75 and a two-hundred day simple moving average of $2.12. The company has a market cap of $95.07 million, a P/E ratio of -1.17 and a beta of 0.59.

aTyr Pharma (NASDAQ:ATYR) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.06). The firm had revenue of $0.19 million for the quarter, compared to the consensus estimate of $0.91 million. On average, research analysts predict that aTyr Pharma will post -0.91 earnings per share for the current year.

Institutional Trading of aTyr Pharma

Several large investors have recently made changes to their positions in the company. Kingswood Wealth Advisors LLC bought a new stake in aTyr Pharma in the 4th quarter valued at about $41,000. JPMorgan Chase & Co. increased its holdings in shares of aTyr Pharma by 157.4% during the third quarter. JPMorgan Chase & Co. now owns 105,817 shares of the company’s stock valued at $76,000 after acquiring an additional 64,710 shares in the last quarter. Millennium Management LLC increased its holdings in shares of aTyr Pharma by 22.0% during the third quarter. Millennium Management LLC now owns 1,890,921 shares of the company’s stock valued at $1,364,000 after acquiring an additional 340,721 shares in the last quarter. Brevan Howard Capital Management LP acquired a new position in shares of aTyr Pharma during the third quarter worth approximately $169,000. Finally, Bank of America Corp DE lifted its holdings in shares of aTyr Pharma by 319.6% in the 3rd quarter. Bank of America Corp DE now owns 177,671 shares of the company’s stock worth $128,000 after purchasing an additional 135,325 shares in the last quarter. 61.72% of the stock is currently owned by institutional investors and hedge funds.

About aTyr Pharma

aTyr Pharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel protein-based therapies that modulate the extracellular matrix and immune pathways. Headquartered in San Diego, California, the company applies its proprietary Extracellular Modulation® platform to identify and optimize biologic candidates for the treatment of rare and serious diseases, including pulmonary sarcoidosis, muscular dystrophy, and solid tumors.

The company’s research efforts are centered on harnessing extracellular proteins to regulate tissue remodeling, cell adhesion, and immune signaling.